Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KD-414 vs Vaxzevria in Adults 18–40 Years Old (COVID-19)
jRCT2031210679Phase 3Completed
- Sponsor
- Meiji Seika Pharma Co., Ltd.
- Start
- Apr 2022
- Modality
- Whole Inactivated Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial of KD-414 in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Meiji Seika Pharma Co., Ltd. Primary endpoint: Primary immunogenicity endpoint. Started Apr 2022; status: completed.
02
Drugs
KD-414
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on jRCT2031210679.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210679.